⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713016 | 0.82 | — | — | |
| SCHEMBL5683250 | 0.80 | — | — | |
| SCHEMBL18043745 | 0.79 | CYP2A6 (0.44) | — | |
| SCHEMBL8058507 | 0.77 | — | — | |
| SCHEMBL4932093 | 0.76 | — | — | |
| SCHEMBL7469721 | 0.76 | — | — | |
| SCHEMBL3525295 | 0.76 | — | — | |
| SCHEMBL1515340 | 0.76 | — | — | |
| SCHEMBL5683854 | 0.76 | — | — | |
| SCHEMBL732161 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| CN-115413238-A | Therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-29 | — | — | CN | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | claimed |
| EP-3887371-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-06 | — | — | EP | claimed |
| CN-113166144-A | Aryl compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| WO-2020109191-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-04 | — | — | WO | claimed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | claimed |
| US-20080004269-A1 | Pyrazolylmethy Heteroaryl Derivatives | NEUROGEN CORPORATION | 2008-01-03 | — | — | US | claimed |
| EP-1807417-A2 | PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006052546-A2 | PYRAZOLYLMETHYL HETEROARYL DERIVATIVES | NEUROGEN CORPORATION (US) | 2006-05-18 | — | — | WO | claimed |
| EP-0428094-B1 | Mevinic acid derivatives | SQUIBB & SONS INC (US) | 1995-10-18 | — | — | EP | claimed |
| US-5173487-A | MEVINIC ACID DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1992-12-22 | — | — | US | claimed |
| US-5045537-A | Treating Diseases Caused by Retroviruses | SANDOZ LTD. (CH) | 1991-09-03 | — | — | US | claimed |
| EP-0428094-A1 | Mevinic acid derivatives | E.R. SQUIBB & SONS, INC. (US) | 1991-05-22 | — | — | EP | claimed |
| US-5001148-A | Mevinic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1991-03-19 | — | — | US | claimed |
| EP-0401784-A1 | Mevinic acid derivatives | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | claimed |